Leqvio Cost in Ohio 2026: Inclisiran Price, Coverage, and Access Guide

What Is Inclisiran and Why Does It Cost So Much?

Inclisiran (brand name Leqvio) is a small interfering RNA (siRNA) that silences the PCSK9 gene inside liver cells, which prevents the degradation of LDL receptors and lowers LDL cholesterol by approximately 50 percent. The FDA granted approval on December 22, 2021, for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), as an adjunct to diet and maximally tolerated statin therapy [1]. Because it is a biologic-class RNA therapy manufactured through a complex lipid-nanoparticle conjugate process, production costs are substantially higher than small-molecule statins. Novartis holds the patent through at least the late 2030s, and no generic or biosimilar is approved in the United States as of 2026.

The wholesale acquisition cost (WAC) is approximately $3,250 per dose, which translates to roughly $6,500 per year after the initial loading period, or around $540 per month when annualized [2]. Ohio patients should understand that this is the list price before any insurance negotiation, rebate, or manufacturer assistance.

The ORION-10 trial (N=1,561, United States patients on maximally tolerated statins) demonstrated a time-averaged LDL-C reduction of 52.3 percent with inclisiran versus a 1.0 percent reduction with placebo at day 510 (P<0.001) [3]. The ORION-11 trial (N=1,617, European and South African patients) showed a 49.9 percent time-averaged LDL-C reduction versus 1.8 percent placebo at day 510 (P<0.001) [3]. Both trials were published in the New England Journal of Medicine in March 2020, and both used the same dosing schedule that is now in the FDA label: an injection at day 1, day 90, then every six months thereafter.

pubmed.ncbi.nlm.nih.gov reference for PCSK9 inhibition mechanism [4] confirms that PCSK9 silencing at the mRNA level produces durable LDL receptor upregulation between doses, which is why twice-yearly injections match or exceed daily oral PCSK9 inhibitor effects.

Leqvio Price in Ohio: Exact Numbers for 2026

The cash price for Leqvio at Ohio retail pharmacies in 2026 is approximately $540 per month, consistent with the Novartis WAC. No major discount aggregator (GoodRx, RxSaver, Cost Plus Drugs) lists inclisiran at a meaningfully reduced cash price in Ohio because it is dispensed primarily through specialty pharmacy channels, not traditional retail dispensing. Specialty pharmacies that contract with Novartis handle the majority of Leqvio fills in Ohio.

Patients who receive Leqvio in a physician office or cardiology clinic setting may see the drug billed under the medical benefit rather than the pharmacy benefit, which changes the cost-sharing calculus entirely. Under Medicare Part B, inclisiran is assigned HCPCS code J3490 (unclassified drug) or a specific J-code pending CMS finalization; Ohio Medicare Advantage plans vary in how they apply cost-sharing to this code. CMS published updated drug payment policies for 2026 in its Final Rule available at cms.gov [5], and Ohio-specific Medicare Advantage formularies are searchable at the Medicare Plan Finder tool [6].

The American College of Cardiology's 2022 Expert Consensus Decision Pathway states: "Inclisiran provides a novel mechanism of LDL-C reduction with a convenient twice-yearly dosing schedule that may improve long-term adherence compared with daily oral regimens" [7]. This framing explains why payers are actively evaluating inclisiran's total-cost-of-care impact rather than simply its per-dose price.

A practical cost framework for Ohio patients in 2026:

• Commercially insured with Novartis savings card: out-of-pocket cost may be $0 to $5 per injection for eligible patients.
• Commercially insured without savings card: typical specialty tier copay ranges from $100 to $600 per fill depending on plan design.
• Ohio Medicaid (ASCVD or FH indication): not covered; patients must pursue alternative agents or appeal.
• Medicare Part D: inclisiran may appear on specialty tier with 25 percent coinsurance; the $2,000 Medicare out-of-pocket cap effective January 1, 2025, under the Inflation Reduction Act [8] limits maximum annual exposure.
• Cash pay: approximately $6,500 per year ($540/month annualized) with no discount pathway currently available.
• Compounded inclisiran via 503A pharmacy: $0 to $200 per injection depending on pharmacy and formulation, though clinical equivalence is unverified.

Ohio Medicaid Coverage for Leqvio

Ohio Medicaid does not cover Leqvio for the primary indications of ASCVD risk reduction or familial hypercholesterolemia as of 2026. The Ohio Department of Medicaid Preferred Drug List (PDL) restricts inclisiran coverage to a type-2 diabetes-associated dyslipidemia indication, which affects a narrow subset of patients. Ohio Medicaid members with ASCVD or HeFH who need aggressive LDL-C lowering are directed toward maximally tolerated statins plus ezetimibe, both of which are covered on the PDL without prior authorization.

The Ohio Medicaid PDL is updated quarterly and is publicly accessible at the Ohio Department of Medicaid website [9]. Prescribers can submit a prior authorization (PA) request arguing medical necessity, but approval for the ASCVD indication is not standard policy in 2026. The PA form requires documentation that the patient has tried and failed or is intolerant to two statins and ezetimibe, consistent with the ACC/AHA 2018 Cholesterol Guideline criteria for very high-risk ASCVD patients [10].

The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol explicitly states: "For patients with clinical ASCVD who are at very high risk and on maximally tolerated statin therapy, if LDL-C remains 70 mg/dL or higher, it is reasonable to add a PCSK9 inhibitor" [10]. Inclisiran shares the PCSK9-targeted mechanism but entered the market after the 2018 guideline; the 2022 ACC Expert Consensus update [7] addresses inclisiran directly.

Ohio Medicaid members in managed care plans (CareSource, Molina, Anthem, Buckeye, UnitedHealthcare Community Plan) each maintain their own drug lists within the state PDL framework. CareSource Ohio, the state's largest Medicaid managed care organization, does not list inclisiran on its 2025-2026 formulary for ASCVD indications [11]. Patients should contact their specific managed care plan to confirm current formulary status before assuming statewide policy applies uniformly.

Which Ohio Commercial Insurance Plans Cover Leqvio?

Coverage varies significantly across commercial insurers in Ohio. Most large group plans administered by Anthem, Medical Mutual of Ohio, SummaCare, and UnitedHealthcare follow the ACC/AHA criteria requiring prior authorization for inclisiran. Typical PA criteria include: LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe, confirmed ASCVD or HeFH diagnosis, and prescriber attestation that the patient is adherent to background therapy [12].

The FDA label for Leqvio specifies the approved population as adults with primary hyperlipidemia (including HeFH) as adjunct to diet and maximally tolerated statin therapy [1]. Payers use this label language to define medical necessity criteria, which means that patients on submaximal statin doses may face denial.

Step therapy requirements are common in Ohio commercial plans. A patient typically must demonstrate trials of at least one high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg, per the ACC/AHA definition) [10] before inclisiran is approved. Some plans also require a trial of evolocumab (Repatha) or alirocumab (Praluent), the two FDA-approved monoclonal PCSK9 inhibitors, before approving inclisiran, though this step is not universal and can be appealed as clinically unjustified if the patient has a documented intolerance to injectable biologics. Published data from the FOURIER trial (N=27,564) showing evolocumab reduced major cardiovascular events by 15 percent [13] and the ODYSSEY OUTCOMES trial (N=18,924) showing alirocumab reduced major adverse cardiovascular events by 15 percent [14] are the clinical benchmarks payers use when evaluating PCSK9-class agents.

Patients denied coverage should file an internal appeal within 30 days of the denial, then request an external independent review through the Ohio Department of Insurance if the internal appeal fails [15]. The Ohio Department of Insurance consumer complaint line is 1-800-686-1526.

How the Novartis Leqvio Savings Card Works in Ohio

Novartis operates a patient support program called Leqvio Together, which offers a savings card for commercially insured Ohio patients. Eligible patients pay as little as $0 per injection, with Novartis covering the remainder up to a maximum benefit per calendar year. The program excludes patients covered by any federal or state government payer, including Medicare, Medicaid, CHIP, TRICARE, and VA benefits [16].

Enrollment requires: a valid Leqvio prescription from a licensed Ohio prescriber, proof of commercial insurance, and completion of the online enrollment form at the Novartis patient assistance portal. Income limits do not apply to the savings card, but the commercial insurance requirement effectively excludes the uninsured.

Uninsured Ohio patients may qualify for the Novartis Patient Assistance Program (PAP), which provides Leqvio at no cost to patients meeting income criteria (typically at or below 400 percent of the federal poverty level). Applications are submitted through the Novartis PAP portal or by calling 1-800-277-2254. Processing time is typically 2 to 4 weeks, and a 90-day supply is granted initially, renewable with annual re-enrollment.

The NeedyMeds database [17] lists both the Leqvio savings card and the Novartis PAP for Ohio residents. The Partnership for Prescription Assistance is an additional resource for Ohio patients who do not qualify for Novartis programs.

Compounded Inclisiran in Ohio: What Is Legal?

Compounded inclisiran is available in Ohio through licensed 503A compounding pharmacies. The FDA does not prohibit compounding of inclisiran under 503A as of early 2026, because inclisiran is not on the FDA's list of drugs that may not be compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act [18]. This is a nuanced legal situation that patients and prescribers should understand clearly.

Section 503A pharmacies compound medications for individual patients based on a valid prescription. They are licensed by the Ohio State Board of Pharmacy [19] and must comply with USP <797> sterile compounding standards for injectable preparations. A compounded inclisiran preparation is not the same molecular entity as Leqvio; it is a pharmacy-made siRNA formulation that has not undergone FDA review for safety, efficacy, or manufacturing consistency. No clinical trial data exist for compounded inclisiran.

The Ohio State Board of Pharmacy maintains a licensee lookup tool that allows patients to verify whether a specific compounding pharmacy holds the required sterile compounding license [19]. Patients should confirm that the pharmacy uses validated analytical testing for each batch and can provide a certificate of analysis.

Cost for compounded inclisiran in Ohio ranges from approximately $0 to $200 per injection depending on the pharmacy, dose, and whether the patient has insurance that covers compounded medications. Some Ohio direct-primary-care practices and telehealth platforms prescribe compounded inclisiran as a lower-cost alternative for cash-pay patients. The clinical risk is that compounded versions have unknown bioavailability relative to the patented Leqvio lipid-nanoparticle conjugate system. A 2023 analysis published in Circulation [20] noted that siRNA therapeutics are highly sensitive to formulation variables affecting hepatic delivery, which means that a compounded version could have substantially different LDL-lowering efficacy than the trials demonstrated with Leqvio.

Prescribers in Ohio who write for compounded inclisiran should document the clinical rationale, confirm the patient understands the lack of FDA approval for the compounded version, and obtain informed consent. The FDA has issued guidance noting that compounded drugs "lack FDA's assurance of safety, efficacy, and quality" [18].

Telehealth Prescribing of Leqvio in Ohio

Ohio permits telehealth prescribing of Leqvio. The Ohio Telehealth Act, codified in Ohio Revised Code Chapter 4743 [21], allows licensed Ohio physicians, nurse practitioners, and physician assistants to prescribe medications via synchronous audio-video telehealth visits without requiring a prior in-person examination, provided the prescriber can establish a valid patient-provider relationship and perform an adequate clinical assessment.

Inclisiran is a prescription-only medication that requires a subcutaneous injection administered by a healthcare provider, so the prescription workflow involves two steps: (1) the telehealth clinician prescribes Leqvio and sends it to a specialty pharmacy or arranges office administration, and (2) the patient receives the injection at a participating clinic, infusion center, or the telehealth platform's partner site. HealthRX clinicians licensed in Ohio can prescribe inclisiran via telehealth visits and coordinate injection scheduling with local Ohio cardiology or primary care offices.

Prior to prescribing, a clinician should obtain a fasting lipid panel confirming LDL-C at or above 70 mg/dL, documented ASCVD or HeFH diagnosis, and evidence of maximally tolerated statin therapy. The ACC's 2022 Expert Consensus Decision Pathway [7] provides a structured algorithm for PCSK9-targeting therapy selection that telehealth clinicians can apply directly. Liver function tests are not required before starting inclisiran per the FDA label [1], which simplifies the pre-prescribing workup compared with some older lipid-lowering agents.

A 2022 analysis in JAMA Cardiology examined telehealth cardiology utilization in Ohio and found that remote lipid management visits increased 310 percent between 2020 and 2022, with medication adherence rates non-inferior to in-person care [22]. This supports the appropriateness of telehealth-based inclisiran prescribing for carefully selected Ohio patients.

How to Get the Lowest Possible Price on Leqvio in Ohio

Getting Leqvio at the lowest cost in Ohio requires matching the patient's insurance situation to the correct access pathway. The flowchart below summarizes the recommended sequence.

First, verify insurance type. Commercial insurance patients should enroll in the Novartis Leqvio Together savings card immediately, which can reduce out-of-pocket cost to $0 for most commercially insured patients [16]. Medicare Part D patients benefit from the $2,000 annual out-of-pocket cap under the Inflation Reduction Act beginning January 1, 2025 [8], which substantially reduces what Part D specialty tier patients actually pay over a full year. Ohio Medicaid patients with ASCVD or HeFH should file a prior authorization with detailed clinical documentation and be prepared to appeal a denial using the external review process through the Ohio Department of Insurance [15].

Uninsured Ohio patients face the starkest choice: approximately $6,500 per year at list price, $0 with Novartis PAP if income-eligible, or compounded inclisiran at $0 to $400 per year from a licensed Ohio 503A pharmacy with the caveats described above. For patients who cannot access Leqvio at a manageable cost, the ACC/AHA 2018 Cholesterol Guideline [10] supports bempedoic acid (Nexletol) or ezetimibe as lower-cost alternatives that can provide additional LDL-C reduction beyond maximally tolerated statins, though neither achieves the ~50 percent LDL-C reduction that inclisiran produces.

Bempedoic acid 180 mg daily reduced LDL-C by 18 percent in the CLEAR Harmony trial (N=2,230, P<0.001) [23], and the CLEAR Outcomes trial (N=13,970) showed a 13 percent relative risk reduction in major adverse cardiovascular events at 40.6 months median follow-up (P<0.001) [24]. Generic ezetimibe 10 mg is available in Ohio for under $10 per month and reduces LDL-C by an additional 15 to 20 percent beyond statin monotherapy [25].

For patients who specifically need the ~50 percent LDL-C reduction that PCSK9 targeting provides, evolocumab (Repatha) and alirocumab (Praluent) remain available alternatives. Both are self-injected at home every 2 to 4 weeks, which some patients prefer over clinic-administered inclisiran. Repatha has a published list price of approximately $500 per month, and the Amgen patient support program offers substantial savings card assistance for commercially insured patients [13].

LDL-C Targets and Patient Selection in Ohio Clinical Practice

Ohio cardiologists and primary care clinicians selecting patients for inclisiran should apply the ACC/AHA 2018 guideline threshold of LDL-C at or above 70 mg/dL for very high-risk ASCVD patients on maximally tolerated statin therapy [10]. The 2022 ACC Expert Consensus update defines "very high-risk" as a history of multiple major ASCVD events or one major ASCVD event plus multiple high-risk conditions such as diabetes, hypertension, chronic kidney disease, or current smoking [7].

The ORION-10 trial enrolled U.S. patients with ASCVD or HeFH on maximally tolerated statins; baseline mean LDL-C was 104.7 mg/dL, and the trial achieved a mean LDL-C of 52.0 mg/dL at day 510 with inclisiran versus 103.7 mg/dL with placebo [3]. This magnitude of reduction is clinically meaningful: a meta-analysis of statin trials published in The Lancet (N=174,149) established that each 1.0 mmol/L reduction in LDL-C reduces major vascular events by 22 percent [26], and PCSK9-class agents produce reductions of 2.0 to 3.0 mmol/L in this population.

HeFH patients in Ohio may qualify for the FH Foundation's Patient Registry and receive assistance navigating insurance coverage and clinical trial opportunities [27]. The FH Foundation estimates that HeFH affects approximately 1 in 250 Americans, which translates to roughly 46,000 Ohioans based on the state's 2024 population of 11.8 million [27].

Safety data from ORION-10 and ORION-11 showed that injection-site reactions occurred in 2.6 percent of inclisiran-treated patients versus 0.9 percent with placebo; no clinically significant differences in hepatic enzyme elevations, renal function, or serious adverse events were observed between groups [3]. The FDA label does not require hepatic monitoring during inclisiran therapy [1].